Telix Pharma Gains on Regeneron Solid Tumor Program Tie-Up

Telix Pharmaceuticals is experiencing a positive market reaction following its collaboration with Regeneron Pharmaceuticals. The partnership focuses on developing radiopharmaceuticals for solid tumor programs, potentially worth up to $2.1 billion in milestones plus royalties. This significant deal underscores the growing interest and investment in targeted cancer therapies and highlights Telix's strategic positioning in the competitive oncology landscape.